| Olaparib for metastatic pancreatic patients with BRCA mutations gains FDA approval The POLO clinical trial looks at whether the PARP inhibitor olaparib improves outcomes for those with metastatic pancreatic cancer after platinum-based chemotherapy. In December 2019, based on the results of this study, the FDA approved olaparib for treatment of pancreatic cancer in people with a BRCA mutation. Read behind the headlines to learn more about this treatment.
Read the Review | 